Prostate Cancer Diagnostics Market Size & Share 2026 - 2035

Prostate Cancer Diagnostics Market Size

The global prostate cancer diagnostics market was valued at USD 5.5 billion in 2025. The market is expected to reach from USD 6.1 billion in 2026 to USD 14.6 billion in 2035, growing at a CAGR of 10.2% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the advancements in diagnostic technologies, growing prevalence of prostate cancer, increasing awareness and screening programs, and expanding geriatric population, among other contributing factors.

Prostate cancer diagnostics is the set of tests and interventions aimed at identifying prostate cancer, evaluating the extent of the disease, and determining the appropriate treatment. To this effect, it comprises PSA testing, various imaging methods, and biopsy procedures that help in confirming and monitoring the condition.

The major players in the global prostate cancer diagnostics market are Roche, GE HealthCare, FUJIFILM, bioMérieux, and SIEMENS Healthineers. These firms keep their competitive position through continuous product innovation, worldwide market presence, and hefty investment in research and development.

The market has increased from USD 3.7 billion in 2022 and reached USD 5 billion in 2024, with a historic growth rate of 16.3%. The market growth was driven by rising uptake of advanced imaging and biomarker-based tests, increasing adoption of early screening programs, and the growing prevalence of prostate cancer among ageing male populations.

As prostate cancer cases surge worldwide, particularly among older men, the demand for early detection tools is witnessing a significant uptick. For instance, according to the World Health Organization (WHO), prostate cancer accounted for over 1.4 million new cases globally in 2021, making it one of the most common cancers among men.

Additionally, the American Cancer Society reported that in 2025, approximately 313,780 new cases of prostate cancer were diagnosed in the U.S. alone. Contributing factors include lifestyle choices, genetic tendencies, and heightened awareness about screenings. Consequently, this growing patient demographic is fuelling the adoption of diagnostic tests.

Furthermore, innovations such as next-generation sequencing (NGS), liquid biopsy, mpMRI (multiparametric magnetic resonance imaging), and AI-enabled imaging have improved accuracy and reduced false positives associated with traditional PSA testing. These advanced technologies support precision diagnosis and staging. Their improved clinical utility drives wider adoption across hospitals and diagnostic centers.

Prostate Cancer Diagnostics Market Trends

The market is growing considerably with the shift toward multiparametric MRI (mpMRI) for initial diagnosis, the rising use of liquid biopsy & non-invasive biomarker tests, and growth of genomic & molecular diagnostics, among other factors collectively driving industry growth.

• mpMRI is being largely utilized pre-biopsy to confirm the diagnosis with higher accuracy and to avoid unnecessary invasive procedures. In fact, it makes it easier to detect only those cancers which are of clinical significance and at the same time, it reduces the number of false positives that are due to a PSA test. Currently, there are many guidelines that endorse mpMRI as a first diagnostic approach, thus its use is becoming widely adopted its use is becoming widely adopted.
  
• Genomic assays such as Oncotype DX, Decipher, and Prolaris are becoming central to risk stratification and personalized treatment planning. These tests provide deeper insights into tumour aggressiveness and recurrence risk. Their expanding clinical acceptance supports precision oncology adoption globally.
  
• Additionally, portable diagnostic devices are becoming more common in primary care and community screening settings. POC PSA tests offer rapid results, improving early detection and patient engagement. This trend is especially notable in regions with limited access to full-scale diagnostic infrastructure, thereby sustaining market growth.
  

Prostate Cancer Diagnostics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on test type, the prostate cancer diagnostics market is segmented into diagnostics tests and imaging tests. The diagnostics tests segment has asserted its dominance in the market by securing a significant market share of 63.6% in 2025 owing to rising adoption of PSA testing, increasing use of advanced biomarker assays, and growing preference for early and non-invasive screening methods. The segment is expected to exceed USD 9.4 billion by 2035, growing at a CAGR of 10.4% during the forecast period.

On the other hand, the imaging tests segment is expected to grow with a CAGR of 9.9%. The growth of this segment is driven by increasing utilization of multiparametric MRI and advanced ultrasound technologies, along with rising demand for accurate tumor localization and staging to guide targeted treatment decisions.

• The diagnostic tests segment continues to dominate the market. The growing number of prostate cancer cases globally is directly increasing the need for early and accurate diagnostic tests. Higher prevalence among ageing men and better awareness contribute to more frequent screenings. This expanding patient base fuels steady demand for PSA, biomarker, imaging, and genomic tests.
  
• Targeted therapies such as PARP inhibitors and hormone-based drugs require molecular testing to identify eligibility based on BRCA1/2 or other mutations. This linkage between treatment selection and diagnostics boosts demand for advanced genetic tests. Precision oncology’s growth is reshaping diagnostic test portfolios.
  
• The imaging tests segment held a revenue of USD 2 billion in 2025, with projections indicating a steady expansion at 9.9% CAGR from 2026 to 2035. The segment is driven by the growing shift toward precision diagnostics, where clinicians rely on high-resolution modalities to differentiate aggressive from indolent tumors more effectively. Additionally, the rising adoption of image-guided biopsy and treatment planning techniques is boosting demand for advanced imaging solutions.
  

Based on cancer type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma, and other cancer types. The prostatic adenocarcinoma segment dominated the market in 2025, accounting for USD 5 billion and is anticipated to grow at a CAGR of 10.4% during the forecast period.

• Prostatic adenocarcinoma accounts for more than 90% of all prostate cancer cases, making it the dominant subtype requiring routine screening and diagnosis. Its high incidence among ageing male populations increases test volumes. This strong epidemiological burden drives continuous demand for PSA tests, biopsies, and imaging.
  
• Adenocarcinoma may develop without any symptoms for years, thus diagnosing it in time is the only way to prevent metastasis. Survival rates improve dramatically with early detection, which is the reason why clinicians are more willing to carry out comprehensive testing. The need for this clinical urgency is what drives the demand for sensitive and specific diagnostic tools.
  
• The small cell carcinoma segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 9.2% over the forecast period. The segment's expansion is attributed to the increased awareness of this subtype as a severely aggressive and hard-to-localize subtype of prostate cancer that necessitates specially designed and sensitive diagnostic approaches. Molecular profiling and advanced imaging to reveal neuroendocrine features have become more popular in clinics, which is therefore facilitating the demand for targeted diagnostic tools.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the prostate cancer diagnostics market is classified into hospitals, diagnostic laboratories, cancer research institutes, and other end users. The hospitals segment dominated the market with a revenue share of 45% in 2025 and is expected to reach USD 6.4 billion within the forecast period.

• Hospitals serve as primary centers for prostate cancer screening, imaging, and biopsy procedures. The increasing rate of prostate cancer is leading to more patients coming for their first check-up and diagnosis. As a result, there is a higher need for PSA tests, MRI, and pathology services in hospitals.
  
• Hospitals are typically equipped with mpMRI, PET-CT, digital pathology, and biopsy devices that are needed for a complete diagnosis of prostate cancer. Their combined system allows for precise staging and identification of the most invasive tumors. As a result, this facility has become a major driver of patient choice and the number of tests has gone up.
  
• The diagnostic laboratories segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 10.6% over the forecast period. The segmental growth is driven by the rising volume of prostate cancer screenings and the growing need for centralized, high-throughput testing facilities that offer accurate biomarker and genomic analyses.
  
• The cancer research institutes segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 10.3% over the forecast period. The segmental is driven by increasing investment in prostate cancer studies and the pursuit of novel diagnostic biomarkers, fuelling demand for advanced testing platforms and collaborative clinical research initiatives.
  

Looking for region specific data?

Download Free PDF

North America Prostate Cancer Diagnostics Market

North America dominated the market with the highest market share of 40.4% in 2025.

The prostate cancer diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Diagnostics tests
  • PSA
  • Prostate biopsy
  • Molecular/ genomic test
  • Other diagnostics tests
• Imaging tests
  • Transrectal Ultrasound (TRUS)
  • MRI
  • CT Scan
  • Other imaging tests

Market, By Cancer Type

• Prostatic adenocarcinoma
• Small cell carcinoma
• Other cancer types

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Cancer research institutes
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE